Neffy, an EpiPen Nasal Spray Alternative, Hits Shelves for Pediatric Patients

Credit: Adobe Stock/JenkoAtaman

ARS Pharmaceuticals has announced that neffy (epinephrine nasal spray) 1 milligram is now available by prescription in the U.S. for children aged 4 years and older who weigh 33 pounds or more, offering a needle-free alternative for treating Type I allergic reactions, including anaphylaxis.

“Many children fear needles, which can lead parents to delay administering needle-based epinephrine treatments. This delay may result in serious consequences,” Eric Karas, chief commercial officer of ARS Pharma, said in a statement. “The availability of the 1-milligram dose before summer travel, camps and back-to-school season will help communities better prepare for allergic emergencies. The needle-free design of neffy also eliminates the risk of adverse events, such as accidental injections into the hands or fingers of a child or caregiver, which happens about 3,500 times each year.”

Approved by the U.S. Food and Drug Administration (FDA) in March 2025, neffy allows younger, school-aged children — who make up nearly 23% of people needing epinephrine — to access emergency allergy treatment without needles, reducing delays and risks tied to injection devices.

The spray is small, portable and easy to use, with human factor studies demonstrating 100% correct administration when following instructions, compared with 35% error rates with injection devices.

The drug is available with a copay savings program for eligible patients to pay as little as $25 for two single-use devices. However, uninsured or underinsured patients may qualify for free product through the ARS Pharma Patient Assistance Program (PAP). The company encourage parents to discuss neffy with health care providers for better preparedness.

“The expanded availability of neffy represents real progress for our community, especially for young children who may be more likely to speak up about symptoms of a serious allergic reaction when they know epinephrine can be given without a needle,” said Sung Poblete, Ph.D., RN, CEO of Food Allergy Research & Education (FARE).

For more information on savings and support programs, visit neffy.com.